1 day ago
5
Prosper Junior Bakiny, The Motley Fool
Thu, Apr 17, 2025, 5:56 AM 4 min read
In This Article:
Equities are down this twelvemonth due to the fact that of Donald Trump's commercialized policies. The 47th U.S. president decided to enforce steep tariffs connected imported goods from astir countries, though helium has since importantly rolled backmost -- oregon astatine slightest paused -- these plans.
Amid each the volatility, immoderate companies are proving resilient by performing overmuch amended than the market. Some of these look similar fantabulous buy-and-hold options, particularly for income-seeking investors. Let's see 2 specified corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).
Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now. Continue »
Although President Trump has spared the pharmaceutical manufacture from tariffs for now, his medication has indicated that could alteration soon. That means drugmakers similar Amgen mightiness spot a meaningful effect connected their bottommost line. According to immoderate CEOs successful the industry, tariffs could adjacent pb to little innovation successful the field. Still, processing lifesaving drugs is simply a concern that volition ne'er beryllium retired of style, careless of economical conditions.
Drugmakers that tin accommodate volition apt execute good successful the agelong run. Amgen is 1 of them. The biotech has a agelong database of approved medicines crossed aggregate therapeutic areas. Last year, it had 13 products that generated astatine slightest $1 cardinal successful yearly sales. Most of these saw their income determination successful the close direction.
Amgen boasts respective breathtaking maturation drivers. Tepezza remains the lone therapy approved by the U.S. Food and Drug Administration (FDA) for thyroid oculus disease.The biotech is aiming for regulatory approvals for this medicine successful different countries, which volition assistance boost its sales.
Amgen's therapy for asthma, Tezspire, co-marketed with AstraZeneca, is besides performing good and continues to grounds important objective wins that volition pb to statement expansions. Older drugs specified arsenic Repatha for precocious cholesterin and Evenity, utilized to dainty the bony illness osteoporosis successful post-menopausal women, are inactive among Amgen's champion performers.
Lastly, the institution has a heavy pipeline. Despite signifier 2 information for its value absorption candidate, MariTide, that failed to impress, this investigational medicine could inactive spell connected to carve retired a coagulated niche successful the fast-growing value nonaccomplishment market. Amgen has plentifulness of different breathtaking programs successful the pipeline.
Amid each the economical issues we person experienced successful the past 5 years, the biotech has continued to summation its dividends. Amgen's payouts person grown by 201% successful the past decade, and it offers a guardant output of 3.2% astatine Wednesday's prices.
English (CA) · 
English (US) · 
Spanish (MX) ·